Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer

Exclusion Criteria

• •Treatment with any other study medicine within 4 weeks before enrollment.
• •Nausea or vomiting ≤ 24 hours prior to registration
• •Ongoing emesis due to obstruction of digestive tract
• •Concurrent use of olanzapine, phenothiazine or amifostine
• •Female with pregnancy or lactation
• •Severe cognitive compromise
• •Known history of CNS disease (e.g. brain metastases, seizure disorder)
• •Concurrent abdominal radiotherapy
• •Chronic alcoholism
• •Known hypersensitivity to aprepitant, tropisetron, or dexamethasone.
• •Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months.
• •History of uncontrolled diabetes mellitus
• •Serious or uncontroled infection
• •Known active HIV, viral hepatitis or tuberculosis infections